Proteomic Aging Clocks Face Their First Real-World Test in a Clinical Trial

For more than a decade, biologists have pursued a deceptively simple question: can aging be measured? Not counted in birthdays, but quantified as a biological state that can rise or fall in response to disease, lifestyle and, crucially, treatment. The most visible answer has been the epigenetic clock, which reads chemical tags on DNA to estimate biological age. Yet blood carries another rich record of the body’s internal state, and in recent years researchers have built so-called proteomic aging clocks from the thousands of proteins circulating in plasma. A new milestone has now moved these tools out of retrospective population studies and into the demanding environment of a randomized clinical trial, a step that a commentary in Nature Biotechnology by Neil A. Robertson and Tamir Chandra of the Mayo Clinic describes as a conceptual leap in aging biomarker capabilities.

The trial in question, reported by Alex Zhavoronkov and colleagues in Nature Biotechnology, marks the first time that six distinct proteomic aging clocks have been deployed together as readouts in a clinical study of an anti-aging intervention. That detail matters because clinical trials are unforgiving environments for biomarkers. A clock that looks impressive when trained on cross-sectional blood samples from tens of thousands of people may behave very differently when asked to detect a modest, treatment-induced change within individuals over months. Robertson and Chandra’s verdict on the exercise is pointed: the deployment revealed more about the clocks themselves than about the drug being tested. In other words, the trial functioned less as a decisive test of a therapy and more as a stress test of the measurement instruments.

To understand why this matters, it helps to consider how proteomic clocks are built. Researchers start with large cohorts in which plasma protein levels have been measured, typically using affinity-based platforms that quantify thousands of proteins simultaneously. Statistical models, often penalized regressions or machine-learning approaches, are then trained to predict chronological age from those protein patterns. The difference between the predicted age and a person’s true age, the so-called age gap, is interpreted as a measure of biological aging. Large-scale efforts published in recent years, including analyses of UK Biobank data by Argentieri and colleagues in Nature Medicine in 2024 and independent work by Xu and colleagues in 2025, showed that such proteomic clocks predict mortality and incident disease with genuine skill, in some cases capturing organ-specific deterioration that epigenetic measures miss.

But prediction in a population is not the same as sensitivity to change in an individual. A clock can be highly accurate at ranking people by age and still be nearly useless for detecting whether a six-month intervention slowed anyone’s aging. Robertson and Chandra frame the trial through this distinction, which echoes a long-standing concern in clinical medicine formalized by Fleming and DeMets in a 1996 paper in Annals of Internal Medicine: a surrogate endpoint must capture the effect of treatment on the outcome of interest, not merely correlate with the outcome in observational data. Correlation across individuals does not guarantee that a biomarker will respond, or respond in the right direction, when a drug perturbs the underlying biology. This is the central technical challenge now facing proteomic geroscience.

The trial also exposed subtler problems that arise when multiple clocks are run on the same samples. Different proteomic clocks are trained on different platforms, different cohorts and different sets of proteins, and they can disagree. Two clocks might both predict chronological age well, yet one might show a treatment effect while another shows none, or even a shift in the opposite direction. Without a validated gold standard, it is difficult to know which clock, if any, is tracking true biological aging rather than platform noise, inflammation from an intercurrent illness, or compositional changes in blood cell populations. Robertson and Chandra emphasize that the six-clock comparison turned this ambiguity into data, allowing the field to see where the clocks converged and where they diverged when confronted with real longitudinal samples from a controlled study.

There is also a deeper statistical issue lurking beneath the age-gap framework. Proteomic clocks are trained to predict chronological age, so by construction the model tends to pull predictions toward the population mean. If a treatment genuinely shifts a person’s protein profile toward a younger state, the clock should register a negative age gap. But the same shift can be produced by regression to the mean, by changes in the overall variance of the proteome, or by the treatment altering the levels of a handful of highly weighted proteins without broadly rejuvenating the system. Dabrowski and colleagues explored related questions in Nature Aging in 2024, examining how clock construction choices shape what the resulting scores actually measure. The trial setting, with its randomized structure and repeated sampling, offers a way to interrogate these artifacts directly rather than speculate about them.

The stakes are high because the geroscience field has been waiting for credible endpoints. Interventions such as rapamycin, senolytic drugs and metformin are being tested in humans with the aim of extending healthspan, yet aging itself is not an approved trial endpoint. The TARGET trial of dasatinib and quercetin, reported by Justice and colleagues in Geroscience in 2018, was an early attempt to pair a senolytic intervention with biomarker readouts, and Moqri and colleagues laid out a systematic framework for biomarker validation in a 2023 review in Cell. What has been missing is the bridge between those frameworks and actual regulatory-grade evidence. A clock that reliably detects decelerated aging in a trial would transform the economics of the field, because trials measuring aging directly could be far shorter and smaller than trials waiting for fractures, infections or deaths to accumulate.

The commentary’s sober conclusion, that the trial taught the field more about the clocks than about the drug, should be read as progress rather than disappointment. First-in-class instruments are always refined through use. The trial provided longitudinal, randomized data against which clock behavior could be benchmarked, something no retrospective cohort can offer. It likely revealed issues of test-retest reliability, sensitivity floors and the influence of acute physiological fluctuations on plasma proteins, all of which are invisible in cross-sectional training data. Robertson and Chandra suggest that this kind of head-to-head deployment, with multiple clocks applied to the same trial samples, is exactly what the field needs to converge on which proteomic signatures are robust enough to carry forward toward validation as surrogate endpoints.

The path forward, as the commentary implies, will require standardization and skepticism in equal measure. Proteomic platforms need consistent calibration across laboratories; clocks need pre-registration and locked algorithms before trials begin, so that researchers cannot select the readout that happens to favor their result; and the field needs studies that test clocks against hard clinical outcomes prospectively, not just against chronological age. The 2026 trial of Zhavoronkov and colleagues will likely be remembered less for any verdict on its experimental therapy and more as the moment proteomic aging clocks left the training ground. If the lessons learned here are absorbed, the next generation of clocks may enter trials not as optimistic proxies but as instruments with documented performance characteristics, bringing the dream of measuring, and eventually modulating, human aging a measurable step closer.

Subject of Research: Validation of proteomic aging clocks as biomarkers in a clinical trial

Article Title: Proteomic aging clocks go to trial

Article References: Proteomic aging clocks go to trial. (n.d.). https://doi.org/10.1038/s41587-026-03361-4

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03361-4

Keywords: proteomic aging clocks, biological age, biomarkers, clinical trial, geroscience, plasma proteomics, surrogate endpoints, epigenetic clocks, longevity research, Nature Biotechnology, age prediction, biomarker validation